TIMP1 and CLDN23 may contribute to adenoma-to-colorectal cancer progression and nominate ruxolitinib for repurposing

Translational Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles